ONCO
Onconetix, Inc.Company Information
- Company Name
- Onconetix, Inc.
- CIK
- CIK0001782107
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ONCO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ONCO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-17
- Last sale
- 2026-04-21
- Shares purchased (TTM)
- 127,190
- Shares sold (TTM)
- 144,172
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,117
- Shares outstanding
- 2,242,770
- Ownership
- 0.63%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 15.65%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Redeemable Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Series C Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Related Party | - | - | - | - | - | - | - | -3 | 0 | 5 | - | - | ||||||
Assets | ||||||||||||||||||
| Series D Preferred Stock | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Series C Convertible Redeemable Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Series A Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | 0 | ||||||
| Series E Preferred Stock | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash | 6 | 4 | 5 | 1 | 0 | 2 | 1 | - | - | 4 | 5 | 8 | ||||||
| Cash And Cash Equivalents At Carrying Value | - | - | 5 | - | - | - | 1 | 0 | 1 | - | 5 | 8 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Receivables Net Current | - | - | 0 | - | - | - | -0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | ||||||
| Assets Current | 7 | 4 | 6 | 1 | 1 | 2 | 1 | 1 | 2 | 6 | 6 | 10 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | 21 | 20 | 21 | 25 | 18 | ||||||
| Goodwill | 10 | 10 | 19 | 18 | 18 | 16 | 27 | 39 | 37 | 47 | 56 | - | ||||||
| Assets | 16 | 15 | 25 | 20 | 19 | 19 | 28 | 62 | 59 | 75 | 88 | 28 | ||||||
Liabilities Current | ||||||||||||||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 13 | ||||||
| Accounts Payable Current | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 3 | 4 | 5 | 3 | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Notes Payable Current | 0 | 0 | - | 0 | 9 | 9 | 9 | - | 10 | 10 | 10 | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Other Notes Payable Current | - | - | - | - | - | - | 9 | 10 | - | - | 10 | - | ||||||
| Warrants And Rights Outstanding | - | - | - | 13 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Derivative Liabilities Current | 1 | 1 | 7 | 1 | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 3 | 3 | 9 | 16 | 13 | 14 | 18 | 17 | 21 | 21 | 17 | 18 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Defined Benefit Pension Plan Liabilities Noncurrent | - | - | - | - | 0 | 0 | 0 | 1 | 0 | 0 | 1 | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | 3 | 3 | 3 | 3 | - | ||||||
| Liabilities | 3 | 3 | 9 | 16 | 13 | 14 | 19 | 21 | 24 | 25 | 22 | - | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | 64 | 64 | 64 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 153 | 148 | 148 | 141 | 135 | 133 | 128 | 120 | 49 | 49 | 49 | 45 | ||||||
| Treasury Stock Common Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -138 | -135 | -131 | -137 | -128 | -125 | -116 | -86 | -82 | -68 | -57 | -34 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | -1 | - | -1 | -1 | -1 | -1 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | -0 | -1 | -0 | -3 | -3 | 1 | -2 | -2 | 2 | - | ||||||
| Minority Interest | - | - | - | - | - | - | - | 7 | 7 | 7 | 7 | - | ||||||
| Stockholders Equity | 13 | 12 | 16 | 3 | 6 | 4 | 9 | 34 | -36 | -14 | 1 | 10 | ||||||
| Liabilities And Stockholders Equity | 16 | 15 | 25 | 20 | 19 | 19 | 28 | 62 | 59 | 75 | 88 | 28 | ||||||
| Notes Payable | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Deferred Finance Costs Current Net | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 4 | 3 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 4 | 3 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOnconetix, Inc. (ONCO) — SEC Financial Statements & Analysis
Onconetix, Inc. (ONCO) is a pharmaceutical preparations company, incorporated in DE. Onconetix, Inc. trades on Nasdaq as: ONCO. Onconetix, Inc. (ONCO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Onconetix, Inc. carries a market cap of $2.53M, a P/E ratio of -0.25x, a P/B ratio of 0.19x, a P/S ratio of 3.92x, an enterprise value of $-3.26M, and an EV/EBITDA multiple of 0.20x. On profitability, it posts a gross margin of 80.40%, an operating margin of -2525.02%, a net margin of -1578.79%, a Return on Equity (ROE) of -105.23%, a Return on Assets (ROA) of -57.37%, and a Return on Invested Capital (ROIC) of -147.75%. Per share, it reports EPS of $-4.55, diluted EPS of $-4.55, free cash flow per share of $-4.60, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -51.33% year-over-year, net income growth of -77.78% year-over-year, and EPS growth of -99.89% year-over-year. On the balance sheet, it maintains a current ratio of 2.21x, a quick ratio of 2.02x, working capital of $3.57M, a debt-to-equity ratio of 0.22x, a debt ratio of 0.18, an interest coverage ratio of -52.44x, free cash flow of $-10.31M (TTM), and net debt of $-5.79M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.53M
- P/E TTM
- -0.25x
- EPS TTM
- $-4.55
- P/B TTM
- 0.19x
- ROE TTM
- -105.23%
- ROA TTM
- -57.37%
- Debt To Equity
- 0.22x
- Free Cash Flow TTM
- $-10.31M
- Net Revenue TTM Growth 1Y
- -51.33%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Onconetix, Inc. in?
Onconetix, Inc. (ONCO) operates in the Pharmaceutical Preparations industry.
What exchange does ONCO trade on?
Onconetix, Inc. (ONCO) trades on the Nasdaq.
Where is Onconetix, Inc. incorporated?
Onconetix, Inc. is incorporated in DE.
When was Onconetix, Inc. (ONCO)'s most recent SEC filing?
Onconetix, Inc. (ONCO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ONCO's market cap?
Onconetix, Inc. (ONCO) has a market capitalization of $2.53M as of 2026-06-30.
What is ONCO's EPS (earnings per share)?
Onconetix, Inc. (ONCO)'s trailing twelve month EPS is $-4.55 as of 2026-06-30.
What is ONCO's ROE (return on equity)?
Onconetix, Inc. (ONCO)'s trailing twelve month Return on Equity (ROE) is -105.23% as of 2026-06-30.
What is ONCO's ROA (return on assets)?
Onconetix, Inc. (ONCO)'s trailing twelve month Return on Assets (ROA) is -57.37% as of 2026-06-30.
What is ONCO's ROIC (return on invested capital)?
Onconetix, Inc. (ONCO)'s trailing twelve month Return on Invested Capital (ROIC) is -147.75% as of 2026-06-30.
What is ONCO's EV/EBITDA?
Onconetix, Inc. (ONCO)'s trailing twelve month EV/EBITDA is 0.20x as of 2026-06-30.